Recognition of the adverse effects of medicinal herbs is not routine and the reports on such effects are even less frequent in clinical practice. Potential herbdrug interactions are of a major safety concern, especially for drugs with narrow therapeutic indices like warfarin, which can lead to severe adverse reactions that are sometimes life-threatening. The interactions between warfarin and medicinal herbs described in the literature have been summarized in this paper relying on Medline database (via PubMed) using the key words: warfarin, herbal supplements and interactions. The references on the analyzed literature have been investigated in order to collect the existing data. The case reports with severe adverse effects such as spontaneous postoperative bleeding, formation of hematomas, hematemesis, melena, thrombosis, subarachnoid hemorrhage and/or subdural hematomas after concomitant use of warfarin and the medicinal herbs: Panax ginseng, Hypericum perforatum, Salvia milthiorizza, Gingko biloba, Serenoa repens, Angelica sinensis, Vaccinium species, Allium sativum, Zingiber officinale, Tanacetum parthenium, Lucium barbarum, Matricaria chamomilla, Boswellia serrata and Camellia sinensis have been estimated. Some of the interactions between warfarin and medicinal herbs have been well assessed proving that they are closely-dependent.
According to the WHO estimation, the global market of herbal products is worth about 60 billion U.S. $ annually and is constantly growing [1] . The recent WHO investigation reports with great concern that 70-80% of the world population, especially in developing countries, relies on traditional medicine, particularly herbal medicines in the treatment of a great number of diseases. The patients usually self-prescribe the herb products without being afraid of the adverse health effects since the herb products are "natural" and are considered as "safe" [2] . Due to the intense, selfprescribed use of herbal products, interactions between these and prescribed synthetic drugs occur very often. In particular, according to results of one survey conducted in January 2010, numerous medical professionals, primarily in the United Kingdom, do not have enough knowledge or interest in herbal medicine, so they should be adequately trained in this field because of the potential undesirable synthetic drugs/herbal medicines interactions [3] .
Warfarin is the most commonly used anticoagulant. It is a coumarin derivative which possesses anticoagulant properties, used to treat or prevent blood clots in veins (deep vein thrombosis) and arteries, pulmonary embolism, chronic atrial fibrillation, and myocardial infarction. Racemic warfarin mixture consists of two optically active isomers, R and S, in approximately equal amounts. Warfarin is rapidly absorbed from the gastrointestinal tract, has high bioavailability and reaches maximum concentration in blood plasma after 90 minutes in healthy volunteers [4] [5] [6] . Racemic warfarin mixture circulates bound to plasma proteins (mainly albumins), accumulates in the liver, where the two isomers are metabolized via different metabolic pathways [7] . The main metabolic pathway for R-warfarin is CYP1A2, whereas for S-warfarin is CYP2C9. On the other hand, the secondary metabolic pathways of R and S-warfarin are identical and are metabolized by CYP3A4, while a small amount of R-warfarin is metabolized through cytochrome CYP2C19 [8] . Half-life elimination of the racemic mixture is 36 to 42 h [7] . Vitamin K is a co-factor in the carboxylation of glutamate residues into γ-carboxyglutamates on the N-terminal regions of K-vitamin dependent proteins (coagulation factors II, VII, IX and X) [9] . Inhibition of the vitamin K conversion cycle by warfarin ( Figure 1 ) induces hepatic production of partially decarboxylated proteins with decreased coagulation activity [10] . Carboxylation enables vitamin K-dependent coagulation factors to bind to phospholipids, thus accelerating the process of coagulation [11] .
Warfarin has a narrow therapeutic index and many drug and food interactions make its safe use difficult for the clinicians. Warfarin therapy should be followed by constant monitoring to prevent potentially life-threatening outcomes due to over-and underanticoagulation. However, even the standard warfarin therapy with the target international normalized ratio (INR) of 2.0-3.0, is associated with major hemorrhage of up to 7-8% annually [12, 13] . Although warfarin interactions with numerous drugs are reported in the literature, few reviews on the interactions between warfarin and herbal drugs have been published so far, and accordingly warfarinherbal product interactions are about to be recognized as one of the challenges in managing an oral anticoagulant therapy. Therefore, the aim of the authors is to provide an overview of the clinical data regarding the interaction between warfarin and medicinal herbs. Case reports, case series and clinical studies have primarily been reviewed and, in the absence of the clinical studies, the in vitro and in vivo studies have been considered. Also, the references on the analyzed literature have been investigated in order to collect the existing data. The interactions between warfarin and certain herbs have been proved directly in either randomized double-blind studies, or, what is more usual, by communicating the individual case reports, and in animal studies. Warfarin activity, examined in the clinical studies or in the case reports, reviewed on the basis of the available literature, is usually obtained by direct estimation of the warfarin concentration in plasma, prothrombin time or by INR. The interactions between warfarin and the medicinal herbs are summarized in Table 1 .
Panax ginseng: Ginsenosides (primarily, panaxadiol and panaxytriol [14] ) inhibit platelet aggregation in vitro and in vivo, prolonged the coagulation time and activated thromboplastin [15] [16] [17] . An open randomized study with 12 healthy volunteers, who were treated with warfarin and ginseng (each capsule contained the extract equivalent of 0.5 g of Panax ginseng root and 8.93 mg ginsenosides as ginsenoside Rg1) concomitantly for seven days, and had previously been treated with ginseng for seven days, indicated that there was not any interaction between ginseng and warfarin. Platelet aggregation, INR, plasma protein binding and the concentration of S-warfarin metabolites were not significantly changed [18] . However, in the randomized, open, double-blind study with 20 healthy volunteers, prothrombin time was decreased and the anticoagulation effect of warfarin was reduced. The subjects were treated only with ginseng (1 g daily, twice as much compared with the previous study) during the first week, and during the second week they were treated either with warfarin (5 mg daily) or placebo. The authors suggested that the ginsenosides, which had stimulated the hepatic enzymes, were responsible for the reduction of prothrombin time and thus increased the metabolism of warfarin [19] . Another double blind randomized study was conducted with 31 volunteers who had undergone heart valve replacement, and who were either receiving concomitantly warfarin and Korean red ginseng (1 g daily) for six weeks or warfarin and placebo for three weeks. The first group presented lower values of prothrombin time compared with the placebo group. Ginsenosides could induce the liver microsomal enzymes and accelerate the metabolism of warfarin [20, 21] . It could be assumed that high doses of P. ginseng (over 1 g daily) seriously changed the pharmacological effect of warfarin and undesirable clinical outcomes could be expected. In a double-blind study, 25 ischemic stroke patients were randomized into 2 groups: the ginseng group (n = 12), given both 0.5 g dry P. ginseng extract and warfarin, and the control group (n = 13), given only warfarin, both groups for 2 weeks. The coadministration of P. ginseng and warfarin did not influence the pharmacological action of warfarin [22] . However, in two case reports (the patient with aortic valve replacement and the patient with atrial fibrillation) a sudden rise in INR due to the combination of warfarin and Panax ginseng were described. In the cases where active bleeding could not be determined, the use of the drug had been terminated and the dosage of warfarin was re-evaluated before discharging the patients [23] . Furthermore, a 58-year old patient with mechanical bileaflet aortic valve prosthesis was admitted with thrombosis caused by inadequate anticoagulant levels that occurred after a period of self-medication with a ginseng product [24] . Contradictory results were reported about the probable interactions between warfarin and P. ginseng, probably due to a different dosage of P. ginseng. Regardless of the fact that there are different presumed mechanisms of the interaction between warfarin and ginseng with consequently different outcomes, the concomitant use of ginseng extracts and warfarin are not recommended.
Hypericum perforatum:
Warfarin interaction with Hypericum perforatum (St. John's wort) reduced the prothrombin time in 22 cases in the period 1998-2002 [25, 26] . An open randomized clinical trial of a possible interaction between warfarin and H. perforatum was conducted with 12 healthy male volunteers divided into two groups. The first group was treated with 1 g of H. perforatum flowers (hypericin 0.825 mg and 12.5 mg hyperforin) twice a day, while the control was not. Both groups received warfarin within seven days. St. John's wort affected the pharmacokinetics of the warfarin racemic mixture, which led to a significant reduction in the area under the curve (AUC-Area under the Curve) and half-time elimination of both warfarin forms, while the clearance of warfarin was significantly increased. On the other hand, St. John's wort did not affect either the maximum concentration or the time required to reach the maximum plasma concentration of warfarin or binding of warfarin to the plasma proteins. However, St. John's wort significantly decreased the pharmacological effect of warfarin since the prothrombin time was reduced. It was proved that St. John's wort induced not only CYP1A2 and/or CYP3A4, because it undoubtedly affected the pharmacokinetics of R-warfarin, but it also induced CYP2C9, as it could be observed on the basis of the altered pharmacokinetics of the S-enantomer [18] , which is consistent with the previous in vitro reports [27, 28] . The study of an upper gastrointestinal bleeding in an 85-year-old male patient with a history of hypertension, old anterior wall myocardial infarction and atrial fibrillation caused by the concomitant use of warfarin and St. John's wort was reported in 2011. Unexpectedly, the patient's INR was increased and a severe bleeding diathesis had been developed, which manifested itself with hematemesis and melena [29] . Since St John's wort contains a number of active ingredients, hyperforin, flavonols, flavonol glycosides, biflavones, naphthodianthrones, acylphloroglucinols, and phenylpropanes [30, 31] , one or more combinations of these active ingredients might affect the drug metabolism of warfarin in sensitive individuals by potentiating its effect on the clotting cascade. The published results indicate that the possible interactions of warfarin with St. John's wort are not exempt, and therefore, this combination should be avoided.
Salvia miltiorrhizza:
Salvia miltiorrhiza (Danshen) proved to be an inhibitor of warfarin hydroxylation due to the inhibition of the microsomal enzymes: CYP1A1, CYP2C6 and CYP2C11 in in vitro and in vivo trials on rats. The active biomolecules, tanshinone I, tanshinone II and cryptotanshinone, extracted from danshen inhibited the formation of 4'-6-and 7-hydroxywarfarin both statistically and significantly in the in vivo studies. Namely, the plasma concentration of warfarin in the experimental rats was elevated by 23% after the concomitant application with danshen ethyl acetate extract [32] . In addition, three cases of the possible interaction between danshen and warfarin were reported [33] [34] [35] [36] . Based on a few case reports, it can be concluded that danshen could intensify the warfarin effect (elevated INR and prothrombin time), and if the co-medication is necessary, the patient should be under constant supervision.
Ginkgo biloba: At least 15 cases are documented with postoperative and spontaneous intracranial bleeding after selfmedication with Ginkgo biloba (ginkgo). Subarachnoid hemorrhage and subdural hematomas after self-medication with ginkgo were also described in the literature [37] [38] [39] [40] . Ginkgolide B, the active principle of ginkgo, which could interact with warfarin, was demonstrated to be a platelet aggregation inhibitor [41, 42] . However, the increased coagulation time, after the concomitant use of ginkgo leaf extract and warfarin, was proved in recent in vivo studies in mice to be the consequence of the bilobalides activity. Namely, bilobalides inhibited the microsomal enzymes CYP1A1 and CYP2C2 and warfarin metabolism [43] . According to the existing study results and the case reports, bleeding can be expected if ginkgo is administered together with warfarin.
Vaccinium:
The interaction of cranberry juice with warfarin was reported in at least 12 cases to the Committee on Safety of Medicines of Great Britain by October 2004. The elevation of INR with or without bleeding was recorded in eight cases. The INR value was unstable in three cases, while in one case the INR level was decreased. The Committee recommended the patients, who were stabilized on warfarin, not to take cranberry juice. If cranberry juice had to be used for medical reasons, the patients should be under constant supervision [44] . Subsequently, the interaction between cranberry juice and warfarin was also reported in several cases by 2006 [45, 46] . Several more cases of the interaction after co-administration were reported from 2007 to 2011 [47] [48] [49] . The patients stabilized on warfarin experienced significant elevation of INR after the administration of cranberry juice in all cases. However, none of the randomized clinical studies confirmed the influence of cranberry juice on the pharmacological effect of warfarin. Namely, in two randomized placebo-controlled studies, involving 30 patients stabilized on warfarin, the patients consumed cranberry (genus Vaccinium) juice for two weeks. Neither statistically significant change of the INR value, nor warfarin concentration were registered in the control group compared with the placebo group [50, 51] . The reports of three more randomized placebo-controlled studies confirmed that cranberry did not affect either the pharmacokinetics or pharmacodynamics of warfarin. The INR value remained unchanged in the control group in comparison with the placebo when cranberry juice was administered in the dosage of 240 mL twice a day [52] , 250 mL once a day [53] or cranberry extract tablets of 100 mg three times a day [54] in both groups, the patients stabilized on warfarin [52, 53] and the healthy volunteers [54] . Furthermore, there was no change in the plasma concentration of warfarin, the degree of binding to the plasma proteins, the platelet aggregation or the activity of coagulation factors II, VII and X; only a mild increment of the INR area under the curve at 90% significance level, which is rarely used, was recorded [53] . Although the existing clinical studies did not detect interactions between cranberry juice and warfarin, the patients stabilized on warfarin should not be treated with cranberry due to a number of the reported possible interactions after their concomitant use.
Allium sativum:
In a double-blind placebo-controlled study of 60 volunteers with cerebrovascular risk factors and constantly increased platelet aggregation, it was demonstrated that the daily ingestion of 800 mg of powdered Allium sativum (garlic) in the form of coated tablets over 4 weeks led to a significant inhibition of the pathologically increased ratio of the circulating platelet aggregates and of spontaneous platelet aggregation. The normalized platelet aggregation was reached after a 4-week wash-out [55] . Additionally, two case reports indicated that an increased intake of garlic extract could cause spontaneous postoperative bleeding and the formation of hematomas [56, 57] , which confirmed the findings of the in vitro conducted studies where garlic oil and its bioactive ingredient ajoene inhibited platelet aggregation induced by different aggregation agents [58, 59] . However, a possible interaction between garlic and warfarin was not reported in an open-label, randomized crossover clinical trial undertaken with 12 healthy male subjects who were pre-treated with enteric-coated garlic tablets, labelled to contain 2000 mg of fresh garlic bulb equivalent to 3.71 mg of allicin per tablet and then treated with a single dose of 25 mg warfarin [54] . The interaction, after the concomitant use of garlic and warfarin, was not detected in this study probably due to the treatment of the healthy male subjects with a single dose, while most of the patients had previously been stabilized on warfarin for a long-time period. Garlic should be avoided before surgery due to the probable inhibition of platelet aggregation.
Zingiber officinale:
In a randomized, double-blind study, 1 g of Zingiber officinale (ginger), administered an hour before surgery, reduced postoperative nausea for 50%. In the same study, ginger had no effect on the prothrombin time after surgery [60] . In another study, 12 healthy male volunteers were pre-treated with ginger (capsules containing 0.4 g of pulverized ginger rhizome) for a week and then warfarin was administrated with either ginger capsules or placebo for seven days. The study indicated that a small recommended amount of ginger neither affected the pharmacodynamics nor the pharmacokinetics of warfarin. Namely, the percentage of warfarin bound to the plasma proteins, the highest plasma concentration, the maximum concentration time and the drug clearance remained unchanged after the concomitant use of the drug and ginger. The bleeding time was not significantly changed after ginger had been introduced in the therapy [61] . However, the study conducted with 20 healthy volunteers (5 g of ginger per day) reported a significant reduction of platelet aggregation in all volunteers [62] . Long and abundant use of ginger could affect platelet aggregation and might increase the bleeding time. Ginger (its active component gingerol) is a strong inhibitor of thromboxane synthetase. It is believed that ginger inhibits the synthesis of thromboxane A2 and stimulates the synthesis of prostacylins which negatively affect platelet aggregation [63] . Small doses of ginger do not affect warfarin activity, but a long and contemporaneous use of ginger in large amounts combined with warfarin should be avoided.
Angelica sinensis:
Only one case report of the possible interaction of Angelica sinensis (dong quai or "female ginseng") with warfarin was described in the literature [64] . Dong quai is rich in coumarins (psoralen, bergapten, osthole, phellopterin, scopoletin, angelols A-H) which are vitamin K antagonists. In addition, ferulic acid, which is a bioactive molecule, inhibits the platelet aggregation process and enhances the warfarin anticoagulant activity. These findings are consistent with the in vitro studies conducted on rabbits which indicated that dong quai did not affect the pharmacokinetics of warfarin, but significantly lowered the prothrombin time values 3 days after the co-treatment with a single dose of warfarin [65] . The possible interactions of dong quai and warfarin should be either accepted or rejected in further studies [66] . The constant monitoring In vitro study [58, 59] Clinical study [55] Clinical study [54] Case report [56, 57] 
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Serenoa repens:
A case of uncontrolled bleeding during surgery when the patient lost approximately two liters of blood was reported. The patient did not mention to his physician the continuous use of Serenoa repens (saw palmetto) for benign prostatic hyperplasia considering it to be natural and hence a safe product [67] . The use of saw palmetto in patients stabilized on warfarin is not recommended without clear medical indications.
Camellia sinensis:
A 44-year-old Caucasian male was stabilized on warfarin with an INR value of around 3.0, after mitral valve replacement. Twenty-two days after surgery, his INR decreased from a stable 3.0 to 1.37. The patient was drinking half a gallon of green tea (Camellia sinensis) per day [68] . The authors of this case report believed that the high content of vitamin K [69] in green tea, which is an antagonist of warfarin, reduced its anticoagulant effect. The long-term co-medication of warfarin and green tea should be carefully monitored.
Boswellia serrata: Two cases of the interaction between Boswellia serrata (boswellia) and warfarin were reported. In both patients the INR values were elevated. Boswellic acid might cause the interaction between boswellia and warfarin since it inhibits lipoxygenase and interferes with COX-1. Furthermore, boswellia could inhibit CYP2C19, CYP3A4 and CYP2C9, the isoenzymes responsible for warfarin metabolism, which emphasizes its anticoagulant activity [70] . Based on current findings, introduction of boswellia in patients stabilized on warfarin is not recommended.
Matricaria chamomilla:
Only one case of the interaction between Matricaria chamomilla (chamomile) and warfarin was reported. Chamomile contains coumarin derivatives, umbelliferone and herniarin, which have a synergistic activity with warfarin and cause an increment in prothrombin time [71] . The simultaneous usage of chamomile and warfarin should be avoided.
Lycium barbarum:
The possible interaction between Lycium barbarum (wolfberry, also called goji berry) and warfarin is postulated in three case reports [72] [73] [74] . The INR ratio was elevated in all three cases, and in one case [72] serious clinical symptoms of epistaxis, bruising and rectal bleeding were described. The authors of these studies assumed that the enhanced effect of warfarin was caused by metabolic interaction and the inhibition of CYP2C9 (Swarfarin pathway) which led to the slow degradation of the Senantiomer. The co-application of warfarin and wolfberry is not recommended until further investigations confirm or deny possible interactions.
Tanacetum parthenium: Tanacetum parthenium (feverfew) neutralizes sulfhydryl groups and inhibits platelet activity [75, 76] . After feverfew extract was applied in the range of 5-50 µg/mL, the inhibition of eicosanoids was found to be irreversible and doseeffective. Feverfew contains sesquiterpene lactones which inhibit the arachidonic acid conversion into prostaglandins and leukotrienes thromboxane A 2 (TXA 2 ), a product of a cascade degradation of arachidonic acid which stimulates the activation of new platelets and increases platelet aggregation [77, 78] . However, in another study on humans, continuous and discontinuous application of a feverfew extract in a period of six months did not change the platelet aggregation [79] . Contradictory results were reported on possible interaction between feverfew and warfarin due to various active components of feverfew which possesses (anti)coagulant activity. Therefore, until the interaction between feverfew extract and warfarin is scientifically proved, the concomitant use should be prevented.
The scientific evidence for the interactions of warfarin with medicinal herbs comes predominantly from in vitro studies, animal studies and individual case reports, while the clinical studies are rare and the meta-studies are not documented in the literature. The obtained results from the in vitro and in vivo studies cannot be extrapolated on humans and hence they cannot be used for a simple prediction of warfarin interaction with herbal supplements in humans. On other hand, the case reports show the side effects of
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Natural Product Communications Vol. 9 (8) 2014 1215 drug-herb interactions, but cannot predict the prevalence of the interaction risks. Besides, specific factors, such as polypharmacy, co-morbidity or even patient's lifestyle, can affect the findings described in the case reports. Additionally, unlike conventional drugs, herbal supplements before the registration for the market are not subjected to the same safety, efficacy, quality, impurity and residue controls. Nevertheless, allergens, pollens, spore or even the series of cultivated herbs can also cause adverse effects. New interactions between warfarin and medicinal herbs can be expected because of the widespread use of herbal supplement therapy and a small therapeutic index of warfarin. Each case report must be well documented, carefully evaluated and revised because such practice can lead to further studies of possible interactions between warfarin and some bioactive molecules of medicinal herbs. Patients stabilized on warfarin are not recommended to be treated with herbal supplements. Co-administration of herbal supplements, when patients are stabilized on warfarin, should be carefully monitored.
